A practice nurse, with sleeves rolled up and a vaccine tray balanced on a stainless-steel trolley, moves briskly between cubicles in a small general practitioner’s office in Kent on a chilly January morning. The waiting area has a slight disinfectant and wet coat odor. In plastic chairs, patients—older couples, parents with young children—check their phones for appointment times. It’s a familiar rhythm. Effective. Nearly imperceptible.
Something is straining, though, behind that rhythm. According to a warning from the British Medical Association, if funding doesn’t increase, some general practitioner practices might stop participating in the flu vaccination campaign next winter. A straightforward figure, £10.06, is at the heart of the conflict. For every flu shot given, practices currently receive that item-of-service fee. The BMA claims that since 2018–19, that rate has not changed.
| Category | Details |
|---|---|
| Organisation Raising Concerns | British Medical Association |
| Current Flu Vaccine Fee (GPs) | £10.06 per jab |
| Last Major Uplift | 2018/19 |
| BMA Proposed Fee | £13.48 per jab |
| Estimated Additional Cost to NHS | Approx. £62 million annually |
| Total Flu Vaccines Delivered (2024-25) | 18.2 million |
| Government Department Involved | Department of Health and Social Care |
| Chief Medical Officer (England) | Chris Whitty |
| Official BMA Guidance | https://www.bma.org.uk |
£10.06 seems accurate and almost generous on paper. In actuality, inflation has subtly eroded it. The cost of staffing has increased. The cost of energy has increased. Requirements for vaccine storage have not changed. What used to seem feasible might now seem insignificant, particularly for smaller practices that are already struggling with narrow profit margins.
The fee would increase by 34% to £13.48 as suggested by the BMA. When multiplied by the 18.2 million doses administered in 2024–2025, the additional £3.42 per vaccine would cost the NHS about £62 million more annually. That amount is not astronomical when considering the size of the national health budget. However, every adjustment becomes political in the current fiscal environment.
In a letter to England’s chief medical officer, Chris Whitty, Dr. Julius Parker, the deputy chair of the GP committee, cautioned that some practices are “no longer financially viable” in taking part in the annual flu program. The language is strong. Deliberate, but not theatrical. As this plays out, it seems that the letter was intended more as a warning that something structural is failing than as a threat.
A further £1.1 billion in general practice funding for 2025–2026 has been mentioned by government representatives as evidence of broader investment. According to the Department of Health and Social Care, the total amount spent on GP contracts is at its highest cash level in more than ten years. That might be the case. However, overall numbers don’t always correspond to sustainability for a given service.
Flu clinics are active businesses. They necessitate additional nursing hours, administrative planning, outreach to patients who are at risk, and occasionally home visits. To further reduce margins, NHS England recently eliminated an extra £10 payment for giving Covid-19 vaccines to patients who are confined to their homes. Whether comparable pressures could prevent practices from focusing on more difficult-to-reach populations this winter is still unknown.
Additionally, the pandemic’s cultural memory is still present. Vaccination campaigns were presented as national missions during COVID-19. Media campaigns, applause, and nightly briefings. Flu shots now seem almost normal again—until funding issues thrust them back into the public eye.
Last season, the NHS distributed 18.2 million flu shots. It’s simple to quote that figure. more difficult to imagine. Consider 18 million rolled-up sleeves, 18 million scheduled appointments, and 18 million electronic system entries. Throughout the fall and winter, it functions as a silent logistical machine. Even a small disruption could have repercussions in the corridors of A&E by January.
GP practices may be criticized for exaggerating the danger. Certain surgeries are required by contract to provide immunization services, especially if they enroll in relevant COVID programs. Additionally, there have been slight increases in childhood vaccination payments. However, the BMA claims that funding for flu shots has actually decreased by more than 25%.
It’s difficult to ignore the timing. Winter pressures on hospitals are still severe, vaccination uptake has shown signs of declining in some groups, and infection rates fluctuate wildly. The necessity of systematic prevention in older populations has been emphasized by Professor Whitty on numerous occasions. Admission is more expensive than prevention. For decades, that reasoning has been valid.
However, infrastructure is essential to prevention. Local disparities may increase if even a small percentage of general practitioner practices decide not to take part in the flu campaign. Demand may be absorbed by larger practices in urban areas. Surgery in rural areas may be difficult. Longer wait times or travel distances may be required for vulnerable patients who are elderly, housebound, or immunocompromised.
The economics of primary care are at the heart of this conflict. Compared to hospital trusts, general practices have narrow profit margins. Even minor financial changes can have existential implications. Sustainability is important even though investors don’t pay much attention to general practitioner offices.
This is brinkmanship, is it? Before contract negotiations, professional associations frequently use more aggressive language. However, it’s also possible that tolerance has weakened as a result of years of small real-term cuts.
One gets a sense of both dedication and exhaustion as they pass a flu clinic at midday and observe the nurses working methodically while the receptionists take calls regarding appointment times. On a ledger, the cost of the flu shot might be £10.06. In reality, it requires goodwill, staffing, and coordination.
It’s unclear if the funding dispute will be settled amicably before September. The NHS has already survived innumerable contract disputes. However, the discussion may quickly become more heated if practices start refusing to order vaccine stock.
Winter has a way of revealing flaws in structures.
Furthermore, the difference between £10.06 and £13.48 might be more significant than policymakers would like to acknowledge for something as unglamorous—and necessary—as a flu vaccine.